Treatment of Low Dose IL-2 and Ganciclovir in Cytomegalovirus Infection
Status:
Not yet recruiting
Trial end date:
2021-03-30
Target enrollment:
Participant gender:
Summary
Cytomegalovirus (CMV) infections is a severe infection in patients of rheumatic disease
treated with corticosteroid and immunosuppressive agents. Ganciclovir is the main therapy in
CMV infection, accompanied with diverse side effects, including neutropenia, anemia, disorder
of renal function and so on, which are also common symptoms of rheumatic diseases.
Additionally, prolonged antiviral treatment may delay recovery of virus, specific immune
responses, resulting in an increasing of late-onset CMV disease.
IL-2 is a pleotropic cytokine which can promote the proliferation and function of CD8+ T
cells and NK cells through the combination with IL-2 receptor. Recently, several studies have
revealed that low dose IL-2 is an effective and safe therapy for autoimmune disease. In
systemic lupus erythematous patients, additionally, patients treated with low-dose IL-2 had
lower incidence of infection with increased percentages of natural killer (NK) cells.
In this prospective clinical trial, we propose to assess the effective and safety of low-dose
IL-2 combined with ganciclovir in the treatment of CMV infection. Meanwhile, we will assess
the immune response of after IL-2 treatment.